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This paper presents a comprehensive overview of the pharmacokinetic parameters used from in
vivo and in vitro studies that are important in order to understand the major conceptual
approaches of toxicokinetics and the disposition of environmental chemicals. In vitro biochemical
information concerning the detoxication of environmental chemicals is also presented. The
discussion leads to a more complete appreciation for the use of in vitro measurements for in vivo
correlations. The concept of interspecies scaling in the interpolation and extrapolation of
fundamental biochemical metabolic processes is illustrated with a number of examples.
Additional examples of in vitro-in vivo correlations are presented in the evaluation of the impact
of chemical exposure to humans. Finally, several important metabolic detoxication enzymes are
presented, including the mammalian microsomal cytochrome P450 and flavin-containing
monooxygenases as well as carboxylesterases and glucuronosyltransferases, to provide insight
into the processes of chemical detoxication in mammalian tissue and blood. Because
interspecies scaling and the pharmacokinetics of chemical disposition have already shown their
usefulness in understanding some examples of chemical disposition, our summary focuses on
showing the usefulness of the pharmacokinetic equations and providing confidence in using the
approach for in vitro-in vivo correlations. Ultimately, the presentation may provide the reader with
a conceptual framework for future evaluation of the human health risks associated with environ-
mental toxicants. Environ Health Perspect 104(Suppl 1):23-40 (1996)
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Introduction
For over 25 years, the concept ofbioacti-
vation ofchemicals to reactive intermedi-
ates that covalently modify critical
proteins and DNA, which in turn alter key
cellular function, ha; been thoroughly
established. Examples ofthe bioactivation
ofchemicals to form toxic substances fol-
lowing the paradigm developed many
years ago (Figure 1) and refined in terms of
mechanism and site of action have been
reported for numerous chemicals including
bromobenzene, acetaminophen, aflatoxin,
polycyclic aromatic hydrocarbons, ary-
lamines, and organophosphates to name a
few (1). The purpose ofthis review is to
present an overview as to how in vitro and
in vivo pharmacokinetic parameters could
be useful in understanding the conceptual
framework for the disposition and detoxi-
cation ofenvironmental chemicals.
While the ability to predict which
chemicals will follow the events oudined in
Figure 1 is instrumental to the prediction
ofto;-;icity ofa chemical, the prediction of
metabolic detoxication could be equally
important. In general, the details ofmeta-
bolic detoxication are less appreciated than
the science ofmetabolic bioactivation of
chemicals to toxic species. This perspective
will focus on the molecular basis for chem-
ical detoxication. Where possible, the
significance ofmetabolic detoxication to
environmental chemicals will be presented.
The detoxication enzymes that will be dis-
cussed in detail include cytochromes P450,
flavin-containing monooxygenase (FMO),
carboxylesterases and other esterases, as
well as glucuronosyltransferases. As a pre-
lude to the presentation ofexamples of
metabolic detoxication ofenvironmentally
relevant chemicals, we wi!l first describe
some general approac'hes to examine the
role of in vitro metabolism studies in the
prediction ofin vivotoxicitydata.
The manifestation ofclinical toxicity of
chemicals is often dependent upon the
peak plasma concentration achieved, the
duration ofexposure to the toxic entity
above aparticular threshold, or the amount
of toxin accumulated in the body. To
determine the exposure to the toxic entity
and to assess the impact ofsuch exposure,
one needs to answer the following ques-
tions: How much ofa chemical gets into
the systemic circulation and to the site or
organ ofbioactivation? Where in the body
will the chemical distribute? How long
does the chemical remain intact in the
body? How does the chemical get elimi-
nated from the body? Is the chemical
metabolized into other entities? Is the toxic
effect derived from the exposed chemical
or from metabolites? How much chemical
in the body is needed to elicit the toxic
effect? Are these toxic reactions reversible?
Thus, an understanding ofthe absorption,
distribution, and elimination ofa specific
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Figure 1. Hypothetical illustration of the metabolic
activation of a chemical to form a toxic metabolite and
the pathological consequences.'
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chemical will allow the prediction of the
occurrence ofpotential toxicities.
The basic principle of toxicokinetics
used in environmental science is directly
derived from pharmacokinetics. Toxico-
kinetic parameters ofa specific chemical in
man can be predicted by allometrically
scaling the corresponding parameters
obtained in animals. These phamacoki-
netic/toxicokinetic parameters in animals
can be obtained from in vivo studies. The
parameter clearance, can be estimated from
in vitrometabolism data also. Derivation of
parameters used in pharmacokinetics can
be found in reviews and textbooks (2-4)
and will not be described in detail here. An
overview ofseveral equations useful for cal-
culating fundamental pharmacokinetic
parameters from in vivo and in vitro data
will be presented, and parameter scaling by
allometry will also be introduced and con-
trasted to physiological modeling.
QuatttngExpour
From in vivostudies in which the chemical
of interest is given to animals, blood or
plasma concentrations ofa chemical at var-
ious time points are usually available and
determined. When steady state is reached
after multiple dosing or with constant
infusion, the concentration (Ca,) can be
predicted as
C55=Fxdose/(txCL) [1]
where t is the dosing period, CL is the total
clearance, and Fis the bioavailability.
The term clearance describes the rate at
which a chemical is eliminated from the
body. Clearance may be calculated as the
available dose (Fxdose) divided by the
area under the systemic chemical concen-
tration-time profile (AUC):
CL=Fxdose/AUC. [2]
Substituting Equation 2 into Equation
1, one will obtain
C55=AUC/t. [3]
Thus, the ability to correctly predict Ci, is
dependent upon the accuracy ofthe mea-
surement ofAUC.
The bioavailability (F) of a chemical
product via various routes of administra-
tion/exposure is defined as the fraction of
unchanged chemical that is absorbed
intact and reaches the systemic circulation
following administration by any route. For
an intravenous (iv) dose of a compound,
bioavailability is defined as unity. For
chemicals administered by other routes of
administration, bioavailability is often less
than unity:
F=AUCnoniv/AUCiv [4]
In many instances, the response to a
particular chemical exposure, particularly
toxicity, is related to the amount of a
chemical in the body rather than to the sys-
temic concentration. The amount in the
body at steady state (Ass) is the product of
the systemic concentration and the steady-
state apparent volume ofdistribution (Vss):
A,,=CG5x Vs. [5]
The apparent volume of distribution
relates the amount ofchemical in the body
to the concentration ofthe chemical in the
blood or plasma. The apparent volume of
distribution does not represent a real vol-
ume. Rather, it is an apparent volume that
should be considered as the size ofthe pool
ofbody fluids that would be required ifthe
chemical was equally distributed through-
out all portions of the body. At steady
state, V., reflects the sum ofthe volumes of
all the pools into which the chemical may
distribute. V,,can be calculated from the
AUMC, area under the moment curve
(i.e., an integration ofthe concentration x
time vs time profile), and AUC as defined
by Benet and Galeazzi (5):
VI =dosejvxAUMC/AUC2. [6]
Half-life (t1/2) is also an extremely use-
ful kinetic parameter for assessing exposure
to a chemical. By definition, half-life is the
time required for 50% of the chemical
remaining in the body to be eliminated. It is
the relationship between the apparent vol-
ume ofdistribution and the total clearance:
tl/2=0.693x V/CL. [7]
If the dosing interval (proportional to
1/exposure frequency) is short relative to
half-life, significant accumulation will occur.
Thus, the half-life parameter allows one to
predict chemical accumulation within the
body and quantitates the approach to
plateau that occurs with periodic or con-
stant toxicological/environmental insult.
Toxins with very short half-lives
may have a smaller impact on human
health because they will have a problem
maintaining concentration levels at which
toxicities may occur. On the other hand,
chemicals with very long half-lives will
accumulate in the body and possess nega-
tive characteristics in terms oftoxicities.
However, if toxicity occurs as a result of
the formation oftoxic metabolites, then it
is the half-lives ofsuch toxic metabolites
that will form a relationship with the level
oftoxicityexposure.
Among the parameters mentioned
above, clearance can sometimes be found
from in vitro studies. For example, if the
total clearance of a compound is related
primarily to oxidative metabolism by the
hepatic cytochromes P450 (i.e., CL =
CLheF), then the in vivo clearance can be
predicted from data obtained from liver
slices, hepatocytes, or liver microsomal
incubation studies. However, it is impor-
tant to note that the accuracy ofthis pre-
diction will be compromised if, for
example, cooperative or competitve bind-
ing to the metabolic enzyme by other sub-
strates occurs in vivo, or substantial
nonspecific binding ofthe substrate occurs
either in vitro or in vivo.
The organ clearance ofa compound can
be limited by any diffusion barrier that
exists between the blood and the organ of
elimination. Ifone assumes zero diffusion
barrier, as well as instantaneous and com-
plete mixing, the simplest model that
describes hepatic clearance in terms of
physiologic parameters is the well-stirred
model (6). The well-stirred model
(Equation 8) states that hepatic clearance
(CLhep with respect to blood concentration)
is influenced by hepatic blood flow (Qhep),
the fraction ofcompound in blood that is
free from plasma protein binding (f,), and
the intrinsic ability ofthe organ to eliminate
a chemical (CLnt). For compounds that are
quickly metabolized, the hepatic clearance
will approach hepatic blood flow. For com-
pounds that are slowly metabolized, hepatic
clearance approximatesf, xCLint:
CLhep=QhepXfuXCLint/(Qhep+fu xCLint)
[8]
The intrinsic ability of an organ to
metabolize a chemical is directly propor-
tional to the activity of the metabolic
enzymes in the organ. Such metabolic
processes are characterized by Michaelis-
Menten kinetics:
Rate ofmetabolism= Vm,, XC/(Km+ C)
[9]
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in whichVmax, the maximum rate at which
metabolism can proceed, is proportional to
the total concentration of enzyme. Km is
the Michaelis-Menten constant corre-
sponding to the chemical concentration
that yields 1/2 of the maximum rate of
metabolism. Dividing both sides of
Equation 9 by the substrate concentration
in the organ (assuming the same free con-
centration at the metabolic site in vitro and
in vivoand in the venous blood) yields:
Rate ofmetabolism/C= Vmax/(Km + C)
=CLhep/fu. [10]
Since identification ofsaturable metab-
olism only occurs for low extraction ratio
compounds (3) (i.e., fuXCLint=CLhep),
the relationship between classical enzyme
kinetics and pharmacokinetics is revealed if
it is assumed that the entire pool of sub-
strate is freely available, and the substrate
concentration is much lower than Km:
fu XCLintIfaf CLint =Vmax/(Km + C)
= Vm./(Km). [11]
The units for Vmax and Km in in vitro
experimental conditions are generally
microgram per minute per nanomole of
metabolic enzyme in the incubation
medium and micrograms per milliliter,
respectively. In the case of cytochrome
P450 isozymes which distribution in the
liver is generally considered to be homoge-
neous, scaling up of the Vmax to describe
the turnover produced by the whole liver
(in the unit ofpig/min) in the well-stirred
model can be achieved (Table 1).
CL = CLhep = Qhep Xfu X(VmaxlKm)
I[Qhep +fuX (Vmax Km)]
[12]
Prediction of Human
Pharmacokinetic Parameters
from Animal Data
Once pharmacokinetic parameters are
obtained via either in vitro methods or
in vivo animal studies, the next crucial task
is to extrapolate them to humans. Two
approaches frequently used are interspecies
allometric scaling and physiological
modeling. Based on an entirely empirical
approach, allometric scaling in general
produces good data for chemicals solely or
primarily eliminated from the body by
processes such as biliary, renal, or pulmonary
excretion. Physiological scaling requires
more data, model designing, mathematical
prowess, and interpretation and is therefore
much more complex. In many instances,
due to the lack ofdata, many ofthe initial
parameters needed in the physiological
model are estimated by allometric scaling.
The allometric approach will be described
in detail, and the physiological modeling
approach will be briefly discussed.
Aliometric Saling
Interspecies scaling is a method ofinterpo-
lation and extrapolation ofthe underlying
anatomical, physiological, and biochemical
similarities in mammals. Many of these
similarities, or differences, are related to
the size of the species. It has been recog-
nized that many ofthe physiological para-
meters (7) that ultimately determine the
values ofvarious pharmacokinetic parame-
ters are related across species according to
their body weights raised to a certain power
(7). This relationship between the rate of
biological processes and body weights is
linked by the metabolically active mass in a
unit termed the ergosome (8). The meta-
bolically active mass is hypothesized to cor-
relate with the rate at which oxygen and
oxidizable materials are delivered to meta-
bolically active cells (8). The size of the
metabolically active mass, or the number of
ergosomes a species has, equals B', where
B, is the body weight, and n is the allomet-
ric exponent (8). Thus, the rationale for
normalizing data on the ordinate by a
power function of body weight is based
upon this premise. Allometric equations
that relate a physiological variable to a one-
term power function used in concert with
the bodyweight are generally represented as
Y=aBn. [13]
It has also been found that, at times,
the single-term power function is incapable
offully characterizing biological and phar-
macokinetic processes for all mammals.
Sacher (9) found that by accounting for
Table 1. Typical values for constants used in in vitro-
in vivopredictions.
Total P450 (nmol) Hepatic blood flow,
Species per whole liver ml/min/kg
Rat 118 69
Dog 1,085 41
Man 2,320 21
Data from DJ Rance (personal communication).
both brain weight (Bw) and body weight
using a two-term power function, i.e.,
Y=axBbX (Bwc) [14]
processes such as the maximum lifespan
potential can be more adequately described
(9). Pharmacokinetic processes such as
intrinsic clearance for compounds elimi-
nated by the mixed function oxidases (10),
when expressed relative to maximum lifes-
pan potential instead of chronological
time, also c6rrelate well with body weight
across species (11-13).
Because the allometric exponents for
most biological processes, with some
exceptions, are less than 1 (7), it is appar-
ent that smaller animals will have smaller
individual physiological variables than the
larger animals. Yet, it was discovered that,
for all species, a constant relationship exists
between particular physiological variables
within each species. For example, the
breath:heartbeat ratio is 4 for all mammals
regardless oftheir sizes (14), or the num-
ber ofheartbeats per maximum life span is
8.6x 108 (15). In other words, smaller
mammals are performing the same physio-
logical functions in the correct relative
quantities but at a much quicker pace than
larger animals.
The notion ofsmaller animals perform-
ing the same physiological functions in the
correct relative quantities but at a much
quicker pace than larger animals leads to the
introduction oftime equivalence as well as
phramacokinetic-space time. The chrono-
logical time on the abscissa is adjusted by a
power function ofbody weight to yield a
time equivalence termed pharmacokinetic
time. Pharmacokinetic time is a species-
dependent unit of chronological time
required to complete a species-independent
pharmacokinetic event (14). Each species
is endowed with its own particular ideal
(mathematical) space-time continuum,
which in turn is related to the organism's
total body mass (8). A summary of the
different pharmacokinetic-space-time
parameters is presented in Table 2 (8,16).
Table 2. A summary of different pharmacokinetic-
space-time units.
Kallynochron Wl-'min
Appolysichrons W-'min
Mesochron 24.5 apl or 5.53 kin
Syndesichrons BYxx BwZx 102 min
Abbreviations: kin, kallynochron; apl, appolysichrons.
Reproduced with permission from Boxenbaum and
Ronfeld (8) and Boxenbaum and O'Souza (16).
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When data for the ordinate and the
abscissa are scaled to a power function of
body weight, concentration-time profiles
of chemicals administered to different
species will collapse into one single profile
as demonstrated in the elementary Dedrick
plot (8,17-19) and the complex Dedrick
plot (8). Ifthe clearance (CL) and the vol-
ume ofdistribution (1V) ofa compound are
defined by the allometric functions
CL=aBXBwZ
and
V=bBs,
coo
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then plasma concentration (C) after an
iv bolus dose is as follows, assuming Z
equals 0:
C=(DIV)e-kt [17]
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Figure 2. Complex Dedrick plot of chlordiazepoxide data. Body weight power on abscissa equals Y-X 0.58-(-0.17).
Units on the abscissa (time/B0O75) are apolysichrons. Allometric volume expressions are solved for liters.
Reproduced with permission from Boxenbaum and Ronfeld (8).
Hence, the parameter on the ordinate
will be normalized by dose per bodyweight
raised to the power ofy, and the time on
the abscissa will be normalized by By-x
(Equation 19). The difference between the
elementary Dedrick plot and the complex
Dedrick plot is that, in the elementary
Dedrick plot, y takes on the value 1.
Examples of such superimposability
between species are found in antipyrine dis-
position (8) using the elementary Dedrick
plot and chlordiazepoxide disposition
(Figure 2) with the complex Dedrick plot
(8). The beauty ofusing allometric scaling
is that pharmacokinetic parameters can be
easily related from one species to another
by a simple expression (8). For example:
t1/2 man=t,/2 dog (Bman/Bdog)YX [20]
Recentwork by Lave et al. (20) reported
that increased accuracy in the prediction of
clearance ofmafarotene, a compound elimi-
nated exclusively by metabolism, can be
achieved by integrating in vitro metabolic
datawith in vivopharmacokinetic data from
animals. In vivo clearance from each animal
species is normalized by the ratio of in vitro
metabolic clearances in the corresponding
animal species and man (Figure 3):
CLrat,normalized= CLratXCLman, microsomes
/CLrat, microsomes [21]
The in vitrometabolic clearances can be
obtained from either hepatocyte or micro-
somal incubation data, as described by
Equation 10. The normalized clearance
values in animals were then extrapolated to
humans using allometric scaling (Figure 3).
Allometric scaling is useful not only in
estimating individual pharmacokinetic
parameters (21-24) but also in estimating
the entire pharmacokinetic profile (25), as
well as toxicity end points (15). It may also
offer a way to determine which larger ani-
mal to use in toxicology testing (15) and
what doses to use in toxicity testing (15);
allometric scaling potentially leads to the
reduction of the numbers of subjects
needed in a study (26).
PhysiologicalModeling
A physiological model is composed of a
series of lumped components (body
regions) representing organs or tissues in
3-
2 -
.a 1
.N
co 0
c -1-
-2 -
-3 -
* Man
Do
Mos Rat
0 Hepatocytes
- -X- - Microsomes
-2 -1 0 1 2
Log, bodyweight
Figure 3. Allometric scaling of clearance of mafaro-
tene normalized with in vitro data obtained from
microsomes (- -x - -) or hepatocytes (-.). For micro-
somes, y=0.823x+1.035, r2 =0.999; for hepatocytes,
y=0.784x+1.024, r2 =0.972. Projected oral clearance
values for man were 5.1 and 4.2 mlemin/kg, respec-
tively. Reproduced with permission from lave et al.
(20). *Represents observed oral clearance in man
(equal to 7.5ml.min/kg).
which concentrations are assumed to be
uniform. The individual components are
connected by a flowsystem representing the
actual blood flow to and from the individ-
ual tissues. The schematic ofa prototypical
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Figure 4. Schematic of a prototypical physiological
model.
physiologic model is shown in Figure 4.
Each model is unique because it tries to
describe various processes under different
physiological constraints. Assumptions
such as those related to the elimination
organs, dose linearity, elimination model,
protein free fraction, blood:plasma ratio,
and restriction and extent ofthe distribu-
tion and transport processes need to be
made before the development of the
model. Equations describing each of the
processes involved in the model are set up
and solved simultaneously, yielding values
for the parameters ofinterest.
Physiologically based pharmacokinetic
modeling is useful for estimating drug dis-
position (27) and toxicity in different
species (28), once the model is described in
detail in one species. It also allows extrapo-
lation from high dose to low dose and vice
versa. As compared to the allometric
approach, it has the advantages of being
capable of describing situations in which
nonlinearities occur, showing the differ-
ences from various routes and frequency of
administration, or making apriori predic-
tions ofpharmacokinetic changes associated
with various disease states, age, pregnancy
(29), or drug-drug interactions. In addi-
tion, physiologically based pharmacoki-
netic modeling can also be used to model
surrogates in tissue compartments (15).
As described above, once pharmacoki-
netic parameters are obtained via either in
vitro methods or in vivo animal studies, the
next task is to extrapolate the information
to humans. Below, we provide an example
of an in vitro-in vivo correlation of an
environmental chemical, (S)-nicotine, to
which humans are widely exposed.
In VtoIn VivoMetabolic
Correiations of(S)-Nicotine
In the United States, approximately 75
million people smoke tobacco (30).
Approximately 400,000 deaths occur every
year in the United States from tobacco
smoking, primarily from lung cancer
and respiratory and heart disease (31).
Recently, it has been concluded that
approximately 3,000 lung cancer deaths
occur in the United States annually from
environmental tobacco smoke in nonsmok-
ers (32). Passive smoking may also be
responsible for some 150,000 to 300,000
cases annually ofbronchitis and pneumo-
nia in U.S. children (31). There are a large
number ofconstituents in mainstream and
sidestream smoke from cigarrettes that
could contribute to the untoward health
effects described for smoking tobacco. (S)-
Nicotine is one of the major components
of tobacco and formation of (S)-cotinine
and (S)-nicotine N-1'-oxide in humans are
useful markers of (S)-nicotine exposure
because both metabolites are chemically
stable and because the metabolites are
formed bydifferent enzyme systems (33).
In vitro kinetic studies showed that in
the presence ofadult human liver micro-
somes, the mean Km apparent value for
formation ofthe iminium ion (that is sub-
sequently converted to (S)-cotinine by the
action ofexogenously added aldehyde oxi-
dase) was 39.6 pM (range 3-75 pM) (34).
Interestingly, of the 13 microsome sam-
ples from which the data were obtained,
three samples gave mean Km apparent val-
ues of482 pM, over 10-fold greater than
the normal mean values. The Km apparent
value for FMO3-mediated (S)-nicotine
N-1'-oxide formation in the presence of
human liver microsomes is probably
greater that 800 pM, almost 20-fold more
than that for cytochrome P4502A6 for-
mation of(S)-nicotineAl'5'-iminium ion.
Thus, the relatively low percent of (S)-
nicotine N-i'-oxide that is formed in vivo
compared with (S)-cotinine probably
reflects the fundamental kinetic properties
ofadult human FMO3 versus cytochrome
P4502A6. In vitro data suggest that
approximately 90% of the formation of
(S)-nicotine A1'5'-iminium ion could be
explained by the action of cytochrome
P4502A6. However, there may be a
cytochrome P4502A6 polymorphism or
differential expression in human liver
preparations, and it is possible that the
intersubject variability in human liver
microsome samples for (S)-nicotine C-
atom oxidation observed may underlie the
large interindividual variability observed
for (S)-nicotine metabolism in vivo. Thus,
use of in vitro metabolic correlations has
identified the type of cytochrome P450
responsible for iminium ion formation
(i.e., CYP2A6); it has provided consider-
able insight into the relative amount of
adult human FMO3 versus cytochrome
P4502A6-mediated (S)-nicotine metabo-
lism; and finally, it has provided under-
standing about the fundamental molecular
basis for interindividual differences in (S)-
nicotine metabolism in humans (Figure 5).
Although considerable interindividual
variability in both the amount of (S)-nico-
tine present and the type of metabolite
formed [i.e., (S)-cotinine or (S)-nicotine
N-1'-oxide] was observed in humans fol-
lowing intravenous, dermal, or free-smok-
ing routes ofadministration, nevertheless,
quantification ofeach metabolite provided
information about two potentially
disparate metabolic pathways [i.e., flavin-
containing monooxygenase-catalyzed for-
mation of (S)-nicotine N-1'-oxide and
cytochrome P450-catalyzed (S)-nicotine
A"5'-iminium ion] (33). The metabolic
formation ofthe N-1'-oxide probably rep-
resents a detoxication pathway for (S)-
nicotine, whereby the polar, highly ionized
N-1'-oxide is readily excreted in the urine.
On the other hand, formation of (S)-nico-
tine Al"5-iminium ion potentially repre-
sents a bioactivation mechanism because
the iminium ion has been shown to cova-
lently modify tissue macromolecules.
The pharmacological activity of
(S)-nicotine Al'5'-iminium ion is poorly
understood, but it is known to be effi-
ciently oxidized by the action ofaldehyde
oxidase to (S)-cotinine. (S)-Cotinine can
also be further metabolized. In humans,
(S)-cotinine metabolites [i.e., trans-3-
hydroxy-(S)-cotinine and (S)-cotinine glu-
curonide] represent major metabolites of
(S)-nicotine (35). Thus, the interindivid-
ual variability in formation ofhuman (S)-
nicotine metabolites (35) may be a
consequence of a number of mechanisms
contributing to detoxication and bioactiva-
tion including the fundamental kinetic
properties of the metabolic enzymes
involved and the wide individual genetic
variability in the formation of additional
(S)-nicotine metabolites [i.e., glucuronida-
tion of (S)-cotinine, 3-hydroxy-(S)-coti-
nine, and (S)-nicotine] as well as more
complicated mechanisms.
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(S)-Nicotine
cis-(S)-Nicotine N'-oxide
(S)-Cotinine trans-3-Hydroxycotinine
trans-(S)-Nicotine N'-oxide
(S)-Cotinine
glucuronide
trans-3-Hydroxycotinine
glucuronide
Figure 5. Scheme depicting the major (S)-nicotine metabolites in humans.
As described above, (S)-nicotine under-
goes extensive Phase I oxidative metabo-
lism in humans, and approximately 90% of
a dose can be accounted for in terms ofuri-
nary metabolites. In the presence of adult
human liver microsomes, cytochrome
P4502A6 appears to be the major enzyme
that forms (S)-nicotine A1"5'-iminium ion
that is converted to (S)-cotinine by alde-
hyde oxidase (36). Because it appears that
cytochrome P4502A6 and aldehyde oxi-
dase work in concert to produce a detoxi-
cated end product of (S)-nicotine, it is
possible that humans with a deficiency of
aldehyde oxidase are predisposed to an
increased risk of the untoward effects of
(S)-nicotine At"5'-iminium ion. In addi-
tion, polymorphism leading to a reduction
in the ability of a subpopulation ofhumans
to metabolize (S)-nicotine by cytochrome
P4502A6 could also result in longer half-
lives of (S)-nicotine and result in increased
pharmacological and behavioral effects.
While the pharmacological and neuro-
chemical effects ofincreased accumulation
of (S)-nicotine A1'5'-iminium ion in
humans who are unable to oxidize the
iminium ion are unknown, they are likely
to be considerably more toxic than expo-
sure to increased levels of the rapidly
excreted (S)-nicotine N-i'-oxide.
Of the two (S)-nicotine N-1'-oxide
diastereomers that could be formed in
humans, the absolute stereoselective forma-
tion ofonly the transdiastereomer has been
used as a selective functional probe ofadult
human FMO activity (33,36). Adminis-
tration of a mixture of (S)-nicotine N-i'-
oxide diastereomers by either free-smoking,
intravenous, or dermal routes to humans
showed that the N-1'-oxide was not appre-
ciably N-1'-oxidized or reduced (33). If
efficient reduction ofmetabolically formed
(S)-nicotine N-1'-oxide to (S)-nicotine in
humans occurred, it could explain the rela-
tively low amount ofN-i'-oxide formed in
vivo. That (S)-nicotine N-1'-oxide reduc-
tion is not observed in vivo (33) suggests
that metabolic futile cycling between nico-
tine N-1'-oxide and tertiary amine does
not provide a reservoir for the pharmaco-
logical action of (S)-nicotine. Thus, previ-
ous reports in animals describing the
reduction of (S)-nicotine N-1'-oxide to
the tertiary amine is probably due to gut
bacteria metabolism via the oral route of
administration (37).
Cytochrome P450 Monooxygenase
The cytochrome P450 superfamily is a
ubiquitous set ofmicrosomal hemoproteins
that are associated with the metabolism of
xenobiotics and endogenous materials. In
the human liver, approximately 20 cyto-
chrome P450s have been characterized to
some extent. In contrast, in animal liver at
least 4 times that number of cytochrome
P450s have been observed. Historically, the
cytochrome P4502B subfamily that has
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been most associated with experimental
animal xenobiotic metabolism has been
referred to as the phenobarbital-inducible
cytochromes P450. Besides the fact that
the human enzyme forms are less numer-
ous than the animal forms, compounds
often induce distinct hepatic cytochrome
P450s in the animal and the human. For
example, although a gene encoding human
cytochrome 2B6 has been identified, a
prominent role for this enzyme form in
adult human liver microsomal metabolism
is not likely. While an extremely large liter-
ature is available concerning the metabolic
activation ofchemicals by the cytochromes
P450 to reactive metabolites, a number
of examples of cytochrome P450-medi-
ated detoxication of xenobiotics to less
toxic materials is available. Generally, cyto-
chromes P450 convert lipophilic com-
pounds to oxidized metabolites that are
commonly more polar and more readily
excreted. Numerous examples in the litera-
ture have shown that this process can result
in metabolically reactive intermediates that
can covalently modify tissue macromole-
cules and cause cell death and ultimately
tissue necrosis (Figure 1). However, cyto-
chrome P450 can also directly catalyze the
conversion oflipohiic compounds to polar,
readily excreted metabolites. Many of the
cytochrome P450 detoxication reactions
are analogous to detoxication reactions
catalyzed by the flavin-containing mono-
oxygenases, although the microscopic enzy-
matic mechanism ofcourse is completely
different. For example, cytochromes P450
can catalyze the N-oxidation of tertiary
amines to the tertiary amine N-oxide, the
S-oxidation ofsulfides (or other sulfur-con-
taining compounds) to their corresponding
sulfoxides, as well as the P-oxidation of
phosphines (and other phosphorous-
containing compounds) to their phospho-
rous oxides. Cytochromes P450 can
oxidize the same substrates to the same
products as the flavin-containing mono-
oxygenase (ignoring the question ofstereo-
chemistry) and contribute to xenobiotic
detoxication. Often, however, heteroatom
oxidation, for example, is not the predomi-
nant reaction, and other less benign reac-
tion products dominate for a particular
substrate. For example, for a tertiary
amine, one often observes extensive N-
dealkylation in preference to N-oxidation,
and this leads to formation of an aldehyde
and an amine. It is not surprising that the
flavin-containing monooxygenase and
cytochromes P450 produce similar prod-
ucts from the same substrate, because in
both cases the monooxygenases employed
possess considerably potent enzyme-bound
oxidizing agents.
Flavin-containingMonooxygenase
The action ofFMO constitutes an impor-
tant means ofterminating the pharmaco-
logical and toxicological action of a wide
number ofxenobiotics including (S)-nico-
tine. As seen for numerous other tertiary
amines, FMO-catalyzed N-oxygenation
converts a biologically active compound
into a polar, readily excreted tertiary amine
N-oxide. FMO also catalyzes the oxygena-
tion oforganosulfur-, selenium-, phospho-
rous- and other heteroatom-containing
chemicals that are likewise more efficiently
excreted after oxygenation. In contrast to
cytochromes P450, FMO generally con-
verts heteroatom-containing compounds to
products with decreased potential for toxic
or carcinogenic properties. Cytochromes
P450 can oxidize nucleophilic heteroatoms
to heteroatom oxides that in some cases are
the same as the products from FMO, but
cytochrome P450 does so considerably less
efficiently than FMO. Another fundamen-
tal difference between cytochrome P450
and FMO is the apparent one- versus two-
electron enzyme mechanism of oxidation
of each monooxygenase, respectively.
Consequently, cytochrome P450-mediated
oxidation has been implicated in numerous
co-oxidative and free radical processes,
many ofwhich are destructive to cellular
macromolecules and tissue. The two-elec-
tron oxygenation mechanism ofFMO does
not preclude the enzyme from participating
in metabolizing some chemicals to toxic
metabolites (38). One notable example is
the conversion ofsecondary arylamines to
the corresponding aryl hydroxylamine.
Another example comes from the N-oxy-
genation ofa tertiary amine to an unstable
tertiary amine N-oxide that undergoes
Cope-type elimination to produce a
hydroxylamine and an olefin (38). It is
possible that the hydroxylamine formed
could possess untoward pharmacological
properties. In principle, FMO-mediated
aryl hydroxylamine formation and subse-
quent esterification or sulfation may
contribute to the carcinogenic properties of
arylamines (39). However, the contribu-
tion ofthis particular aspect ofarylamine
metabolism has not been fully addressed
because many ofthe animal models used in
carcinogenicity testing do not possess high
levels ofthe hepatic form ofFMO present
in adult humans. For example, although it
is recognized that there are five distinct
FMO gene subfamilies encoding five
forms ofmammalian FMO, the most func-
tionally prominent form of the enzyme
in adult human liver (i.e., FMO3) appar-
ently is not present to a great extent in
adult rat liver, a commonly used animal
for drug and chemical metabolism and
toxicity studies (38). Less is known about
the factors that control FMO regulation;
hormone and dietary factors appear to
regulate FMO expression, but this is
species and tissue specific and probably
occurs independently ofother factors.
As discussed above, it is likely that the
major form ofFMO in adult human liver
is distinct from that present in many exper-
imental animals. Regardless, it has been
observed that in species which are deficient
in FMO, shunting ofthe metabolism ofa
toxin to the cytochrome P450 pathway
occurs and makes the animal quite suscep-
tible to the toxic properties of the chemi-
cal. On the other hand, animals with
relatively high levels of FMO may effi-
ciently detoxicate the chemical and are
significantly less susceptible to the toxic
properties ofthe toxin (40). It is believed
that FMO has evolved to detoxicate nucle-
ophilic heteroatom-containing chemicals
or their metabolites present in plants that
would otherwise inactivate or be metabo-
lized by cytochrome P450 or covalently
modify critical tissue macromolecules.
Thus, determining a role for FMO in the
detoxication ofendogenous and xenobiotic
chemicals to which humans are exposed
could constitute an important aspect of
risk assessment.
Carboxylesterases and
Detoxication ofChemicals
Carboxylesterases have long been studied
with regard to their role in detoxication of
drugs and environmental chemicals. To
understand the role ofcarboxylesterases in
the detoxication ofchemicals in humans, a
significant amount ofwork has been con-
ducted using enzyme preparations from
rats and other animals. The carboxylesterase
enzymes used in the studies reported in the
literature were obtained mainly from the
liver ofanimals that contained the greatest
activity ofcarboxylesterases. While hepatic
enzymes from animals have provided
a convenient source of a model enzyme,
differences in substrate specificity have
prompted researchers to use the human
enzyme directly. To provide a direct supply
of the enzyme from human sources, car-
boxylesterase (human esterase D) has been
recently cloned and sequenced, and its
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specific role in detoxication has begun to be
examined. Notwithstanding the recent
advances in the study ofthe recombinant
human enzyme, the current understanding
ofthe role ofcarboxylesterase in the detoxi-
cation ofchemicals has largely been extrap-
olated from in vitro and in vivo studies in
the rat. One caveat to correlations ofthis
type is the fact that rats have higher endo-
genous levels of carboxylesterases than
primates, and this difference could account
for the lower sensitivity of rats to xenobi-
otics that are more toxic as the ester than as
the hydrolysis product (41). Where possi-
ble, this review will examine the specific
role of human esterase D (EsD) in the
detoxication ofxenobiotics. However, some
information from rats (or other animals)
will be presented because this information
is relevant to the possible role ofEsD in the
detoxication ofchemicals in humans.
Carboxylesterases catalyze the hydroly-
sis ofester, thioester, and sometimes amide
bonds during the course ofmetabolism of
xenobiotics and endogenous chemicals
(Figure 6). Generally, formation of more
polar readily excreted products by hydroly-
sis oflipophilic esters to carboxylic acids
constitutes a detoxication process. While
many animal and nonspecific human car-
boxylesterases have been reported in the lit-
erature, few highly substrate-selective
human liver carboxylesterases have been
described. In animals, carboxylesterases are
widely distributed in different tissues. The
large amount ofcarboxylesterase in various
animal tissues in part compensates for the
relatively low specific activity of the
enzyme. Detoxication studies with xenobi-
otics have not yet been fully examined with
the purified human EsD. Most ofthe EsD
data for humans have been inferred from
studies utilizing human serum or analo-
gous carboxylesterases isolated from rats or
other mammals.
OrganophosphorusCompounds
One of the most studied detoxications of
environmental relevance is the hydrolysis
oforganophosphorus insecticides. In the
United States, almost 40 billion pounds of
organophosphate insecticides are used
every year. Thus, organophosphate insecti-
cides comprise an important group of
chemicals to which humans are exposed.
Metabolism and detoxication ofthe mala-
thion-type organophosphorus insecticides
are among the mostwell studied. Generally
in this class ofcompounds, there exists the
phosphorodithionate or phosphonodithio-
nate moiety, as well as a distal carboxylic
acid ester. For such compounds, the distal
carboxylic acid ester is the primary target
ofcarboxylesterase action, which results in
the hydrolysis and formation ofthe detoxi-
cation product containing the correspond-
ing carboxylic acid (Figure 7) (42-44).
Although malathion-type carboxyl ester
hydrolysis and detoxication primarily
occur in the liver and plasma, it has been
shown that human carboxylesterase found
in the skin also functions to detoxicate
organophosphates (45). However, when
malathion-type compounds are subject to
metabolic activation to the corresponding
oxon, the hydrolysis ofthe carboxylic acid
does not occur-rather inhibition of the
carboxylesterase by the phosphonothiolate
moeity is the preferred fate (Figure 8)
(46). For the oxon metabolite, detoxica-
tion is the result ofstoichiometric seques-
tering by the enzyme rather than a result of
0
II
R-C-X-R
catalytic hydrolysis by carboxylesterase.
A similar metabolic fate has been shown
for simple phosphorothionates (e.g., chlor-
pyrifos, Figure 9) when biotransformed to
the oxon in mouse or rat (47-50). It is
notable that in in vivo studies in the rat,
liver carboxylesterase is indeed inhibited
faster than the target brain cholinesterase
byparaoxon (51). This is also the case with
organophosphates and organophosphites in
which no metabolic activation is necessary.
Such compounds have recently been exam-
ined with carboxylesterase derived from
human monocytes (52); the conclusion
was that organophosphates and organo-
phosphites (with the exception of alkyl-
phosphates) are potent inhibitors ofhuman
monocyte carboxylesterase.
Also ofrelevance for a role ofcarboxyl-
esterase in detoxication is the mole-
cular basis for the poisoning events with
0
R-C-OH + HX -R
X=O,S, or NH
Figure 6. Hydrolysis of an ester, a thioester, or an amide to a carboxylic acid and an alcohol, a thiol, or an amine,
respectively.
CH30-7P'Sl 02C2H5
CH30
Malathion
s CA0CH
CH30- kCO2H
CH30 P-monoacid
or
i C02H
CH30-"'%S LCO2C2H5
CH30 -ma a-monoacid
Figure 7. Hydrolysis of malathion esters.
CH3--7Sd-'NS C02CH3
C2H50
Phosphonodithioate
CH3<Y%NS Sd C02CH C2H50/
3
Oxon
t Carboxylesterase
CH3-T2z.p,
CH30/~l
Phosphonylated carboxylesterase
Figure8. Oxidative desulfuration of an organothiophosphorous insecticide to the oxon.
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organophosphorus nerve agents developed
for chemical warfare. This is ofparticular
importance because ofthe recent terrorist
poisoning in Japan using sarin. It has been
shown in rats that irreversible binding of
soman to liver and plasma carboxylesterase
accounts for a significant portion of its
rapid detoxication ofthe soman P(-) iso-
mers. In contrast, the P(+) isomers are
largely detoxicated by A-esterases (Figure
10) (53). Thus, the proposed role ofEsD
'
C2H50
Chlorpyrfos
in humans, on the basis ofstudies in the
rat, is that detoxication ofsoman occurs
when it is sequestered by EsD before it can
reach target tissues containing acetylcholin-
esterases. For soman and other organophos-
phates, this represents an important part of
the mechanism ofcarboxylesterase-medi-
ated detoxication (54). Another example of
stoichiometric sequestration of a nerve
agent is the detoxication oftabun by car-
boxylesterase. Studies with rats showed that
C2H5Cr -FCl
C2H50 Chlorpyrifos oxon
Carboxylesterase
C2H5Of"'0
C2H5cOt,*
Phosphorylated carboxylesterase
Figure 9. Oxidative desulfuration ofchlorpyrifos tothe oxon.
H3 gx
(CH3)3C *%F
Soman P(-) Isomers
0 3 F
(CH3)3C 0O / %sF
CH
H3 o
(CH3)3C O IsO
Carboxylesterase Phosphonylated carboxylesterase
A3 R
A-Esterase ( ) C H 'oH
Soman P(+) Isomers
Figure 10. Phosphonylation ofcarboxylesterase, by soman and hydrolysis of soman byA-esterase.
Table 3. Some environmental contaminant esters thatare detoxicated bycarboxylesterases.
Ester class Chemical example Carboxylesterase References
Herbicides Fluazifop-butyl Human liver, skin, (56)
(Carboxylic esters) plasma (57)
Carbamate Carbofuran Rat (58)
Pyrethroids Permethrin, cypermethrin Adult rat (59,60)
Acrylates Methyl, ethyl, butyl acrylate Mouse nasal mucosa (61)
Glycol monoalkyl Ethylene, propylene Mouse nasal mucosa (61)
ether acetates
Trichothecenes T2 toxin Rat liver (62-64)
Nicotinic acid esters Human plasma (65)
Nitrosomides and Rat liver (66)
nitrosocarbamates
carboxylesterase serves as a protective mech-
anism against tabun by decreasing the
amount available to the target site (i.e.,
intraneuronal acetylcholinesterase) (55).
DetoxicationofChemicals
ofEnvironmental Concern
Carboxylesterase has also been shown to
have a role in the detoxication ofvarious
environmental chemicals. Some representa-
tive compounds are shown in Table 3. The
mode ofcarboxylesterase-mediated detoxi-
cation ofthe compounds listed in Table 3 is
hydrolytic cleavage ofa carboxylic acid ester
moiety to give the corresponding carboxylic
acid and alcohol (Figure 11). Other meta-
bolic processes can and do occur for the
compounds listed in Table 3, but hydrolysis
by carboxylesterase is generally looked upon
as a means ofproducing more polar materi-
als with considerablyless toxicpotential.
Hydrolysis ofDrug
Carboxylesterases in the liver, gut, and
other tissues have been shown to be impor-
tant in the hydrolytic detoxication ofcer-
tain drugs (67). Representative examples
ofdrugs ofthis class that are substrates for
carboxylesterases are listed in Table 4. In
addition, carboxylesterases have been
shown to be efficient hydrolytic catalysts
for a number ofphysiologically important
compounds including steroid and lipid
esters. Recently, the characterization of a
human liver carboxylesterase that hydro-
lyzes and transesterifies (-)-cocaine has
been reported (73). The product of
(-)-cocaine hydrolysis by this esterase is
benzoylecgonine, a metabolite that is
largely inactive as a pyschomotor stimulant
(Figure 12). The Km value for formation of
benzoylecgonine (i.e., 116 WM) is much
greater than the concentration of
(-)-cocaine reported to be in the blood fol-
lowing a 100 mg intravenous dose of
(-)-cocaine (i.e., 3 ,uM) and, presumably
under such subsaturating conditions of
substrate concentration, the human liver
carboxylesterase would contribute to the
detoxication of(-)-cocaine only ifthe Vma.
values were sufficiently great. Interestingly,
the same enzyme also possesses transes-
terification activity. Thus, in the presence
of ethanol and (-)-cocaine, human liver
carboxylesterase catalyzes the formation of
cocaethylene. Although the Km value for
ethanol is relatively high (i.e., 43 mM or
approximately 180 mg/100 ml ofblood),
because the reported range ofblood alco-
hol in individuals that have died from
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(C4H9
F(QayLopbuy
Fluazifop-butyl
Carbofuran
Table 4. Some drugs detoxicated by human
carboxylesterase.
Drug Carboxylesterase source References
Aspirin Purified from human liver, (68)
intestinal mucosa
Clofibrate Purified from human liver, (68)
intestinal mucosa
Procaine Purified from human liver, (68)
intestinal mucosa
Cocainea Purified from human liver (69)
Meperidine Human liver (70)
Mebeverine Human plasma (71)
Lorazepam Human liver (72)
3-acetate
'Hydrolysis ofthe methyl ester of cocaine.
Permethrin
CH3<0 .,,"OH
(CH3)2CHCH2 O CH3
AcO OH3
T2 toxin
Figure 11. Some examples of environmentally important esters that are hydrolyzed by carboxylesterase.
Cocaine
H3C-N 0
OH
Benzoylecgonine
11
H3C-N
I OCH3
Ecgonine methyl ester OH
Ecgonine
Cocaethylene
Figure 12. A scheme showing the hydrolytic metabolism and reesterification of cocaine.
(-)-cocaine overdose is reported to be in the
range of30 to 460 mg/lOOml, it is possible
that transesterification of (-)-cocaine with
ethanol constitutes a metabolic pathway
contributing to increased toxicity of
(-)-cocaine (73). Thus, in addition to the
well-recognized serum cholinesterase or
butyrylcholinesterase that catalyzes the
hydrolysis of (-)-cocaine to ecgonine
methylestester, a new human liver car-
boxylesterase has been discovered that
hydrolyzes the methyl ester of (-)-cocaine
to a pharmacologically inactive metabolite
(i.e., benzoylecgonine) and a pharmacolog-
ically active transesterification product,
(-)-cocaethylene (Figure 12) (73). Possibly
the balance between (-)-cocaine ester
hydrolysis and transesterification for any
particular human subject may contribute
to the overall susceptibility of the individ-
ual to the toxic properties of (-)-cocaine.
To date, the relative amount ofesterase-cat-
alyzed transesterification versus hydrolysis
of xenobiotics has not been extensively
examined. It is likely that the relative bal-
ance between these two competing meta-
bolic pathways may represent another
means ofpredicting the potential for toxic-
ity ofcarboxyl ester-containing xenobiotics.
Cloning, Sequencing, andTissue
Localization of Human Esterase D
Human esterase D (EsD, carboxylesterase,
aliesterase, EC 3.1.1.1) is one of several
nonspecific esterases identified in human tis-
sue that contribute to the hydrolytic detoxi-
cation or metabolism ofxenobiotics, drugs,
and enviromental chemicals. Like other
human esterases (paraoxonase/arylesterase,
sterol esterase, and carboxyl ester lipase), the
physiological function of EsD is not well
understood. EsD is, however, distinguish-
able from other esterases by its specificity for
the hydrolysis of4-methylumbelliferyl esters
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(74,75). The natural substrate for this
enzyme has recently been identified as 0-
acetylated sialic acid, and one suggested
endogenous role ofEsD has been hypothe-
sized to involve the reuse ofsialic acids (76).
Purification of EsD has been accom-
plished from human erythrocytes (77-79),
and the biochemical properties of the
purified enzyme have been reported. EsD
is an enzyme with a molecular weight of
34 kDa as determined by sodium dodecyl
sulfate polyacrylamide gel electrophoresis;
the Km ofEsD for the substrate 4-methyl-
umbelliferyl was determined to be 10 pM.
It is interesting to note that mercuric
chloride and p-chloromercuribenzoate
both inhibited the purified enzyme com-
pletely at low concentrations (1.0 mM),
which suggests that an SH group is neces-
sary for the enzymatic reaction (77). In
addition, purification ofEsD allowed the
preparation ofpolyclonal and monoclonal
antibodies from rabbit and mouse, respec-
tively, that have been useful for immuno-
quantification studies.
The EsD gene (from human erythro-
cytes and human liver) has now been
cloned and sequenced (78,80-83) and has
been localized to chromosome 13 band
q14 (78,80-87). EsD has been shown to
exhibit strong homology to two other
esterases [i.e., acetylcholinesterase (AChE)
from Torpedo californica and esterase-6 of
Drosophila] (81). Homologous regions
were detected about the consensus
sequence serine-containing active site
region. From studies of sequence homol-
ogy, the active site is believed to contain
the peptide isoleucine-phenylalanine-
glycine-histidine-serine-methionine-
glycine-glycine. The residues thought to
participate in catalysis are serine, histidine,
and aspartic acid (82). The human liver
carboxylesterase gene has also been recently
cloned and characterized (83,87j88); it
showed significant sequence homology to
various mammalian carboxylesterases.
Furthermore, sequence analysis ofhuman
liver carboxylesterase and the genes for
human cholinesterase and cholesterol
esterase suggests an evolution from a com-
mon ancestral gene (88).
Although EsD was known to be present
in a variety of tissues, quantification has
only recently been accomplished by using
the specific substrate 4-methylumbelliferyl
acetate (77). The results from this study
showed that most EsD activity was found
in the liver. Significant activity, although
less than that of the liver, was also identi-
fied in the human kidney. Although little
EsD enzyme activity was observed in the
lung, recently a carboxylesterase from the
lung (i.e., alveolar macrophage) has been
purified and appears to be identical to EsD
(89). The results suggest that EsD in the
lung may play a role in the detoxication of
inhaled xenobiotics. Carboxylesterase has
also been identified in human blood
monocytes (52,90). Another site that has
been observed to contain carboxylesterase
activity is the human skin (45), which sug-
gests that EsD may play a role in the
detoxication ofabsorbed xenobiotics.
Carboxylesterase activity has also been
identified in human nasal tissue, suggesting
a role of this tissue in the detoxication of
inhaled xenobiotics as well (91). However,
hydrolysis ofcertain inhaled esters has been
correlated to lesions ofthe olfactory epi-
thelium in rats due to transformation of
inhaled chemicals into toxic substances
rather than detoxicated metabolites (90,92).
The data suggest that hydrolytic metabo-
lism of inhaled esters in this tissue may
play a significant role in the bioactivation
ofsuch substances rather than degradation
and detoxication. It is possible that accu-
mulation of some of the metabolites of
inhaled esters contributes to the pathogen-
esis of ester-induced nasal lesions. In like
fashion, it has been suggested that car-
boxylesterase-mediated hydrolysis ofvinyl
acetate generates acetaldehyde, an intracel-
lular cross-linking agent possibly contribut-
ing to tumorigenesis (93).
The hydrolysis of lipophilic esters is a
major route for the detoxication of envi-
ronmental chemicals such as pesticides.
Human exposure, either from occupa-
tional or passive administration, may
occur via absorption by the skin or the
respiratory tract. Therefore, carboxyl-
esterase-mediated hydrolysis ofxenobiotics
in these tissues, as well as in the liver, may
contribute to influencing the toxicity of
potentially toxic esters.
Paraoxonase/Arylesterase (A-estrase)
It is worthy to briefly discuss the enzyme
paraoxonase/arylesterase in light ofthe pre-
vious presentation of the metabolism of
organophosphorus compounds. Para-
oxonase/arylesterase has been shown to
hydrolyze and therefore detoxicate many
phosphate esters or phosphorothionates
(i.e., organophosphorus insecticides) that
have undergone metabolic activation to the
oxon structure (Figure 8) before these
compounds reach the target tissues con-
taining acetylcholinesterases. Two paraox-
onase/arylesterases that possess the ability
to hydrolyze paraoxon and a variety of
organophosphorus compounds, as well as
arylesters, have been identified in human
serum (94-96). One was shown to be an
ethylenediaminetetraacetic acid (EDTA)-
sensitive esterase while the other was
identified as an EDTA-insensitive paraox-
onase. The highest levels of activity have
been found in liver and serum. Like many
other esterases, no known endogenous
substrates for paraoxonase/arylesterase have
been identified. It has been shown that cal-
cium is required for paraoxonase/arylester-
ase, but the mechanism for the interaction
with calcium is unknown at this time
(97,98). Recently it has been shown that
the enzyme is not a cysteine esterase as
commonly thought for many years; the
mechanism of mammalian paraoxonase/
arylesterase must be reconsidered in light
ofthis new finding (99).
Conclusion
Studies ofthe role of purified EsD in the
metabolism and detoxication of various
xenobiotics are scant compared with the
information available employing other
mammalian enzyme systems. It is clear,
however, that EsD plays a significant role
in catalyzing the detoxication of xenobi-
otics containing carboxylic esters. In addi-
tion, EsD also appears to play a role in the
detoxication of potent anticholinesterase
agents (i.e., organophosphates), not via
catalysis but rather as stoichiometric scav-
engers (i.e., as a binding protein). With the
recent aquisition of the purified human
enzyme as well as the cDNA cloning and
expression of the genes, a clearer under-
standing of the role of EsD in xenobiotic
detoxication may be obtained in the near
future. Furthermore, with careful in vitro
studies of these purified enzymes, in vivo
predictions may be made with an apprecia-
tion for in vitro-in vivo correlations.
Glucuronidation ofXenobiotics
as aDetoxication Pathway
Formation of glucuronide conjugates of
xenobiotics represents one of the most
important Phase II reactions. Glucuro-
nidation is a major detoxication pathway
in all vertebrates examined, from fish (100)
to human (101); glucuronide metabolites
constitute some of the most significant
xenobiotic-detoxicated metabolites in bile
and urine. The key enzyme of the overall
process known as glucuronidation is uri-
dine diphosphate glucuronosyltransferase
(UDPGT), a membrane-associated enzyme
that catalyzes the transfer ofthe glucuronyl
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group to a large number of endogenous
compounds and xenobiotics (Figure 13).
The role of glucuronidation in the
detoxication of environmental chemicals
and carcinogens, whether ingested, inhaled,
or absorbed, is related to the other detoxi-
cation pathways that have been described
above: relatively lipophilic chemicals are
converted to highly polar materials that are
relatively efficiently excreted in the bile and
urine. Glucuronosyl conjugates generally
possess totally different physiochemical
properties compared to those ofthe parent
compounds. For example, the conjugates
are very water soluble, are generally less
toxic, and are rapidly excreted in the urine.
After formation, a glucuronosyl conjugate
may be immediately excreted or acted
upon by hydrolases, which leads to sequen-
tial first-pass effects on the glucuronosyl
conjugate. The glucuronosyl conjugate can
also reenter the liver cell and undergo
enterohepatic recirculation. Glucuronides
can be hydrolyzed in the gut (probably by
bacteria that consume saccharides and leave
the parent compound to be reabsorbed
into the splanchnic circulation). Thus,
pharmacokinetics and processing of glu-
curonide conjugates differ somewhat from
those ofother polar detoxication metabo-
lites that we have discussed above. Because
glucuronosyl conjugates are anions, entry
into and out ofhepatocytes is also depen-
dent on the properties of the conjugate
toward the organic anion transporter.
COOH OH
H OH I I
OH OH 0
OH OH
Uridine-5'-diphospho-a-D-glucuronic acid
COOH
H O -X-R
H
H OH
+
Glucuronide
Metabolites of some environmental
chemicals that are known carcinogens or
toxins have been shown to be glucuro-
nidated and detoxicated; however, there is
some evidence that glucuronosyl conju-
gates ofmetabolites oftoxic materials can
be carriers of carcinogenic activity and
exert an effect in cells quite distinct from
initial glucuronidation. Thus, in cells that
do not possess large polycyclic aromatic
hydrocarbon hydroxylase activity, it has
been observed that polycyclic aromatic
hydrocarbons have significant toxicity. It is
possible that carcinogens are transported
from sites ofhigh monooxygenase activity
(i.e., the liver) to sites that possess low
monooxygenase activity which are never-
theless selective targets (i.e., bladder) after
hydrolysis of the glucuronide moiety
(Figure 14). Included in the list ofchemi-
cals that could participate in this carrier
phenomenon are metabolites ofaromatic
hydrocarbons [i.e., benzopyrene (102),
benzene (103), and 2-hydroxybiphenyl
(104)]; aromatic amines [2-acetylamino-
fluorene (105), heterocyclic arylamines
(from meat and fish in typical household
cooking practices) (106)]; and many other
compounds (Table 5).
FunctionofGlucuronosy lnfras
inDetoxication
The functions ofUDPGTs in detoxication
can be best understood in the context of
overall xenobiotic metabolism. A large
+ R-X-H
OH
0 NI
H--P-O-.P-O-CH2
I I UH OH O
HH
OH OH
Uridine diphosphate
Figure 13. Conjugation of a nucleophile (i.e., R-X-H) with uridine-5'-diphospho-a-D-glucuronic acid to form the
glucuronide and uridine diphosphate.
number of environmental chemicals, as
well as endogenous lipophilic chemicals,
are converted by Phase I enzymes ofdrug
metabolism to a variety ofnucleophilic and
electrophilic metabolites (Figure 15)
(107). It has been shown that chemically
reactive, electrophilic metabolites can inter-
act with critical cellular macromolecules
which can initiate cell toxicity and play an
important role in the multistage carcino-
genic process (108). In many cases, elec-
trophilic metabolites are enzymatically
transformed by Phase II reactions. This is
not to minimize the importance ofother
enzymatic and nonenzymatic metabolic
processes in the bioactivation ofxenobiotics
to reactive intermediates. For example, in
the polycyclic aromatic hydrocarbon series,
phenols can be oxidized to reactive species
including polyphenols, semiquinones, and
quinones. Quinones may also undergo
quinone-quinol redox cycles with the gen-
eration ofreactive oxygen species that have
also been implicated in cellular necrosis
Cell with large monooxygenase
activity(i.e., hepatocyte)
Chemical metabolite
Metabolite glucuronidation
Glucuronide transport to othercell with
lowmonooxygenase activity(i.e., bladder)
Glucuronide hydrolysis
Chemical metabolite
Alteration ofcellularfunction
Figure 14. Hypothetical scheme depicting the metabolic
bioactivation and glucuronidation of a procarcinogen,
which is transported to another cell that possesses low
bioactivation capacity and, nevertheless, accumulates
sufficient metabolite to showsignificanttoxicity.
Table 5. Environmental procarcinogens bioactivated in
one cell and carried to another cell type by glucuron-
idation.
Environmental chemical References
Benzopyrene (102)
Benzene (103)
2-Hydroxybiphenyl (104)
2-Naphthylamine (104)
2-Acetylaminofluorene (2-AAf) (105)
4-Aminobiphenyl (105)
N-[4-(5-Nitro-2-furyl)-2-thiazolylI (106)
formylamide(FANFT)
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COOH
HO H
H OH
Acyl glucuronide
[Acyl migration]
Reaction with
nucleophiles or chemical
rearrangements
Covalent modification
of macromolecules
Untoward effects
(e.g., allergenicity, fatal
hepatotoxicity)
Figure 15. Hypothetical explanation of how an acyl
glucuronide can participate in the covalent modifi-
cation of cellular targets and eventually cause toxicity.
(109). In the arylamine class ofcompound,
N-oxidized aromatic amines can be con-
verted to eletrophiles via oxidation to
hydroxylamines and subsequent sulfation
and/or acetylation (110). The disposition of
Phase I metabolites by glucuronidation
almost certainly contributes to the detoxica-
tion of metabolic products, but glu-
curonidation may also participate in the
bioactivation ofxenobiotics and transport of
potentially toxic species to extrahepatic cells.
Evaluation ofthe toxic potential ofenviron-
mental chemicals must take both processes
into consideration.
Environmental Chemicals
andGlucuronidation
Aromatic amines have been widely used in
the dye industry and were among the first
chemicals to be recognized as human
carcinogens. As early as 1895, a German
physician, Ludwig Rehn (111), suggested
that urinary bladder cancers found in dye
workers were due to chemical exposure to
certain aniline dyes. Aromatic amines
such as 2-naphthylamine and 4-aminobi-
phenyl (Table 5) have been found in nano-
gram amounts in cigarettes (112). These
compounds may account, at least in part,
for the positive correlation between ciga-
rette smoking and the incidence ofbladder
cancer in humans (113). In 1941, 2-acetyl-
aminofluorene (2-AAF), a proposed insec-
ticide, was shown to be carcinogenic to the
liver, mammary gland, and urinary bladder
of rats after dietary administration (114).
2-AAF is one ofthe most extensively stud-
ied chemical carcinogens. The N-hydroxy
metabolites of2-AAF have been found to
be more carcinogenic than the parent com-
pound (108). It was also found that sulfa-
tion and acetylation/deacetylation reactions
led to even more reactive intermediates
that formed covalent adducts with DNA
(107). Formation ofthe N-O-glucuronide
of the corresponding N-hydroxy-2-AAF,
N-hydroxy-2-naphthylamine, and N-
hydroxy-4-aminobiphenyl have been
reported. N-O-glucuronides are semistable
transport forms of the aromatic amines;
they are excreted via the blood into the uri-
nary system and have the effect ofdetoxica-
tion (115,116). However, it is possible
that the same transport form may also con-
tribute to delivering the aromatic amine to
an extrahepatic site and increasing the toxic
potential ofthe amine at that site.
Another example ofan environmental
chemical, 2-hydroxybiphenyl, is widely
used as an antimicrobial agent to protect
edible crops, and it is possible that the
human population may be exposed to it.
However, it is likely that human exposure
to 2-hydroxybiphenyl does not pose a
significant health hazard because, at low
doses, 2-hydroxybiphenyl is efficiently
excreted as a glucuronide and as a sulfate
ester; no significant toxicity has been
observed (104,117).
Mechanismof
Glucuronosyltransferases
Uridine-5'-diphospho-a-D-glucuronic acid
(UDPGA, Figure 13) is the donating coen-
zyme during the glucuronidation reaction.
The UDPGTs are a group of closely
related membrane-bound enzymes that are
responsible for the transfer of the glu-
curonosyl group from UDPGA to many
endogenous and exogenous chemicals hav-
ing nucleophilic functional groups (i.e., X
in Figure 13). The mechanism ofthe glu-
curonidation catalyzed by UDPGTs is
envisaged to take place via an SN2 reac-
tion-the nucleophilic group of the sub-
strates attack the C1 of the pyranose acid
ring ofUDPGA-which results in the for-
mation ofthe glucuronide (Figure 13). As
shown in Figure 13, the attacking groups
of the substrates should have sufficient
nucleophilic character for a high rate of
glucuronidation. There is a wide variety of
groups that fulfill this requirement, e.g.,
phenols (phenol, morphine), carboxylic
acids (bilirubin, valproic acid), alcohols
(t-butanol, many steroids), and hydrox-
amic acids (N-hydroxy-2-acetylaminofluor-
ene) to form O-glucuronides; thiophenols
(thiophenol), and carbamic acids (diethyl-
dithiocarbamic acid) to form S-glucuro-
nides; and aromatic amines (aniline),
hydroxylamines (N-hydroxy-2-naph-
thylamine), and tertiary amines (cyprohep-
tadine) to form N-glucuronides (Table 6).
Even carbon atoms can attack the C1 atom
of the glucuronic acid ring if the carbon
atom is sufficiently nucleophilic (sulfin-
pyrazone, phenylbutazone) to form C-
glucuronides (118) (Table 6). The
reactivity toward forming a glucuronide
will depend on the chemical structure,
including both electronic and steric factors.
A second requirement for a high rate of
enzymatic glucuronidation is for sufficient
lipid solubility ofthe substrate.
The resulting glucuronide is usually
devoid of any significant biological and
pharmacological activities. A family of
homologous UDPGT isoenzymes is
located in the endoplasmic reticulum of
the liver, as well as in other tissues (119).
Purification of the transferases catalyzing
glucuronidation proved difficult because the
enzyme was found to be anchored in the
membrane ofthe endoplasmic reticulum
(120); however, the difficulties involved in
Table 6. Examples ofdrugs and chemicals that undergo glucuronidation.
Glucuronides Functional group Chemical examples
O-Glucuronides Phenols Phenol, morphine
Alcohols t-Butanol, various steroids
S-Glucuronides Thiophenols Thiophenol
Thiols 2-Mercaptobenzothiazole
N-Glucuronides Aromatic amines Aniline
Hydroxylamines N-Hydroxy-2-naphthylamine
C-Glucuronides 1,3-Dicarbonyl compounds Phenylbutazone, sulfinypyrazone
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purifiying homogenous preparations ofa
single UDPGT isoform have now largely
been overcome by the use ofrecombinant
DNA technology. The cloning ofUDPGT
cDNAs and their subsequent expression in
tissure culture by transfection techniques
have proven to be useful tools for determin-
ing the structure and function of a large
number ofUDPGTs, especially the elusive
human UDPGTs. Several UDPGT cDNA
sequences (including bacteria, murine,
virus, bovine, rat, and human) have been
identified (120-124). The expression of
UDPGT cDNA in cell culture can be used
to identify the limits ofsubstrate specificity
of the individual isoenzymes and as a sys-
tem for study of substrate transport, glu-
curonidation, and export of glucuronides
in whole cells in vitro (91).
The study ofUDPGTs in humans has
also shown that several diseases are directly
related to these enzymes. Crigler-Najjar
syndrome is a familial form of severe
unconjugated hyperbilirubinemia caused by
a dysfunction in bilirubin glucuronidation
in humans (125-127). Gilbert syndrome is
a benign, mild, unconjugated hyperbiliru-
binemia that is found in approximately 5%
ofthe population (128-130).
As described previously, although it
seems that most xenobiotic glucuronides
are detoxicated via the action ofUDPGTs,
glucuronidation may also lead to toxic
effects in certain cases, especially at high
dose levels. A well-studied example is
choleresis by glucuronides. In general, glu-
curonide excretion in bile causes choleresis
ofapproximately 15 to 20 pil bile jimol-'
glucuronide (131). However, the phenolic
drug hormol causes cholestasis at a high
dose in the rat because harmol glucuronide
is excreted to such a high extent in bile that
the glucuronide precipitates and the bile
channel becomes blocked (132). As dis-
cussed above, glucuronosyl conjugates can
reenter the liver and hydrolyze back to the
original substrate as shown in Figure 15 in
an apparent metabolic cycling process.
There is no doubt that this is also a factor
in any glucuronide-mediated toxicity.
It is possible that glucuronosyl conju-
gates can become chemically reactive
intermediates and participate in further
metabolism, such as acyl glucuronide
formation (Figure 15). For example, tol-
metin, the nonsteroidal anti-inflammatory
drug used for the treatment ofrheumatoid
arthritis may be converted to a reactive acyl
glucuronide that contributes to adverse
side effects observed in humans. In
humans, tolmetin is primarily metabolized
by oxidation on the methyl group of the
phenyl ring and by conjugation ofthe car-
boxylic acid to produce the O-acyl glu-
curonide. The O-acyl glucuronide may
hydrolyze, participate in acyl migration
reactions, or covalently bind to human
serum albumin. It is the irreversible bind-
ing of tolmetin glucuronides to human
serum albumin that is thought to be
responsible for the allergenic properties of
tolmetin. It is possible that other non-
steroidal anti-inflammatory agents also pos-
sess this unfavorable property. In addition,
it is likely that other carboxylic acids that
participate in acyl glucuronidation may
likewise produce metabolic intermediates
that covalently modify important cellular
proteins and produce untoward effects.
Regulation of
Glucuronosyltransf;erases
Most investigations ofthe regulation ofglu-
curonosyl transferases have been conducted
in animals, even though some in vivo and
in vitro studies have been done in humans
(133,134). Study of the regulation of
UDPGT levels related to different diets has
been conducted in the rat. The results sug-
gest that an iron-deficient diet can cause
depression in UDPGT enzyme activity
(135). Rats fed a diet rich in turmeric can
significantly elevate UDPGT activity (136)
but a vitamin E-deficient diet had no effect
on the activities of UDPGT (137). Most
experimental data about UDPGTs have
been obtained from rats, chickens (138),
rabbits (139), and monkeys (129) in vivo
and in vitro, but the data and theory may
be able to be applied to humans.
The importance of Phase II reactions
by UDPGTs in humans and other animals
has also been investigated (139,140).
However, in vivo studies of humans are
limited, even though there are some
research groups that have investigated the
formation of glucuronides in humans
through the analysis of urine and bile
(141,142). Pharmacokinetic modeling of
drug conjugates in vitro has been well
established such that steady-state rate equa-
tions for the simulation ofconjugation and
deconjugation reactions have been devel-
oped (107). Simulations with mass-
balance equations have proven useful in the
understanding ofconjugation and deconju-
gation processes in vivo (143). Through
these efforts, a more quantitative interpre-
tation of metabolic data on conjugation
reactions has been obtained.
Concluding Remarks
An examination of the pharmacokinetic
parameters that contribute to some of the
major conceptual approaches to understand-
ing toxicokinetics and the disposition of
environmental chemicals has been pre-
sented. By the use of in vitro measurements
and in vivocorrelations, it is possible to pre-
dict with a good deal ofcertainty the extent
ofmetabolic clearance and other important
kinetic parameters. Determination ofclear-
ance invariably leads to a clearer under-
standing ofthe contribution, ifany, to the
toxicity ofa drug or the residence time ofa
potentially toxic metabolite. The concept of
interspecies scaling in the interpolation and
extrapolation offundamental biochemical
metabolic processes has been presented. In
the future, we anticipate that physiological
modeling and allometric scaling will
undoubtedly play an increasingly important
role in predicting the toxicity of environ-
mental chemicals in humans from studies
in animals. It is likely that the use ofscaling
methodologies will also reduce the cost of
evaluating the possible toxicity ofa chemi-
cal to humans. A number ofexamples of
important metabolic detoxication enzyme
reactions have been listed to provide insight
into the breadth ofdetoxication processes
occurring in mammalian tissue; this list of
metabolic processes is not exhaustive. We
anticipate that the list ofwell-studied
detoxication enzyme reactions will increase
in the future. The datawill provide a frame-
work to use the pharmacokinetic informa-
tion outlined here to give useful in vitro-
in vivo correlations to help us understand
the mechanism of action of important
chemicals ofenvironmental concern.
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